A Phase 1 interventional study of [14C]-GDC-9545 and GDC-9545 Solution for Infusion in Healthy Volunteers, sponsored by Genentech, Inc.. Completed at 1 site in United Kingdom. Open to female participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-02.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is an open-label, single-center, two part study in healthy female subjects of non-childbearing potential to investigate the absorption, metabolism, and excretion of [14C]-GDC-9545 (Part 1), the absolute bioavailability of formulations F12 and F18 (i.e., GDC-9545/F12 capsule, 30 mg and GDC-9545/F18 capsule, 30 mg) and relative bioavailability of GDC-9545 oral capsule F18 to the F12 formulation (Part 2). It is planned that Part 1 will begin prior to Part 2 of the study, and that the two parts of the study will partially overlap.
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
First submitted after Genentech, Inc. became part of Hoffmann-La Roche.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be enrolled to receive a single dose of Carbon-14 labelled \[14C\]-GDC-9545.
Drug: [14C]-GDC-9545
Participants will be randomly allocated to one of two treatment sequences (BCD for this arm). In each treatment period, participants will receive a single dose of GDC-9545 in the fasted state in each of three treatment periods. The three treatment periods will be separated by a treatment-free washout between each study drug administration.
Drug: GDC-9545 Solution for Infusion · Drug: GDC-9545/F12 Capsule · Drug: GDC-9545/F18 Capsule
Participants will be randomly allocated to one of two treatment sequences (BDC for this arm). In each treatment period, participants will receive a single dose of GDC-9545 in the fasted state in each of three treatment periods. The three treatment periods will be separated by a treatment-free washout between each study drug administration.
Drug: GDC-9545 Solution for Infusion · Drug: GDC-9545/F12 Capsule · Drug: GDC-9545/F18 Capsule
Participants will receive a single oral dose of \[14C\]-GDC-9545 capsule, 30 milligrams (mg) (not more than \[NMT\] 4.6 megabecquerel \[MBq\]; 124 microcurie \[μCi\]) with approximately 240 millilitres (mL) water in the fasted state.
Also known as: Giredestrant, RO7197597, RG6171
Treatment B: 30 mg GDC-9545 as a solution for infusion, 3 mg/mL administered intravenously (IV) in 10 mL as an infusion over 30 minutes.
Also known as: Giredestrant, RO7197597, RG6171
Drug page: Giredestrant
Treatment C: GDC-9545/F12 capsule, 30 mg, administered orally with approximately 240 mL water.
Also known as: Giredestrant, RO7197597, RG6171
Drug page: Giredestrant
Treatment D: GDC-9545/F18 capsule, 30 mg, administered orally with approximately 240 mL water.
Also known as: Giredestrant, RO7197597, RG6171
Part 1: Mean Cumulative Amount of Total Radioactivity (CumAe) of [14C]-GDC-9545 Excreted in Urine, Feces, and Total (Urine and Feces Combined) Over the Entire Collection Period
Following a single oral dose of 30 milligrams of \[14C\]-GDC-9545, urine and fecal samples were collected over time from each participant. The amounts of total radioactivity excreted in the samples were determined using liquid scintillation counting. The lower limits of detection in urine and fecal samples were 0.423 and 8.36 nanogram equivalent of free drug per gram of sample, respectively. Following Day 21 (480 hours), where urine/fecal collections were no longer continuous and spot sampling days commenced, interpolation of Ae was calculated to estimate the amount excreted on non-collection days (collection intervals with interpolated values included 480-648 hours, 672-816 hours, and 840-984 hours).
Time frame: From Day 1 to Day 42 (0-1008 hours)
Part 1: Mean Cumulative Amount of Total Radioactivity Expressed as a Percentage of the Radioactive Dose Administered (CumFe) of [14C]-GDC-9545 Recovered in Urine, Feces, and Total (Urine and Feces Combined) Over the Entire Collection Period
Following a single oral dose of 30 milligrams of \[14C\]-GDC-9545, urine and fecal samples were collected over time from each participant. The amounts of total radioactivity excreted in the samples were determined using liquid scintillation counting. The lower limits of detection in urine and fecal samples were 0.423 and 8.36 nanogram equivalent of free drug per gram of sample, respectively. Following Day 21 (480 hours), where urine/fecal collections were no longer continuous and spot sampling days commenced, interpolation of Ae was calculated to estimate the amount excreted on non-collection days (collection intervals with interpolated values included 480-648 hours, 672-816 hours, and 840-984 hours).
Time frame: From Day 1 to Day 42 (0-1008 hours)
Part 1: Mean Amount of Total Radioactivity (Ae) of [14C]-GDC-9545 Excreted in Urine, Feces, and Total (Urine and Feces Combined) by Collection Interval
Following a single oral dose of 30 milligrams of \[14C\]-GDC-9545, urine and fecal samples were collected over time from each participant. The amounts of total radioactivity excreted in the samples were determined using liquid scintillation counting. The lower limits of detection in urine and fecal samples were 0.423 and 8.36 nanogram equivalent of free drug per gram of sample, respectively. Following Day 21 (480 hours), where urine/fecal collections were no longer continuous and spot sampling days commenced, interpolation of Ae was calculated to estimate the amount excreted on non-collection days (collection intervals with interpolated values included 480-648 hours, 672-816 hours, and 840-984 hours).
Time frame: 0-12, 12-24, 0-24, 24-48, 48-72, 72-96, 96-120, 120-144, 144-168, 168-192, 192-216, 216-240, 240-264, 264-288, 288-312, 312-336, 336-360, 360-384, 384-408, 408-432, 432-456, 456-480, 480-648, 648-672, 672-816, 816-840, 840-984, & 984-1008 hours
Part 1: Mean Cumulative Amount of Total Radioactivity (CumAe) of [14C]-GDC-9545 Excreted in Urine, Feces, and Total (Urine and Feces Combined) by Cumulative Collection Interval
Following a single oral dose of 30 milligrams of \[14C\]-GDC-9545, urine and fecal samples were collected over time from each participant. The amounts of total radioactivity excreted in the samples were determined using liquid scintillation counting. The lower limits of detection in urine and fecal samples were 0.423 and 8.36 nanogram equivalent of free drug per gram of sample, respectively. Following Day 21 (480 hours), where urine/fecal collections were no longer continuous and spot sampling days commenced, interpolation of Ae was calculated to estimate the amount excreted on non-collection days (collection intervals with interpolated values included 480-648 hours, 672-816 hours, and 840-984 hours).
Time frame: 0-24, 0-48, 0-72, 0-96, 0-120, 0-144, 0-168, 0-192, 0-216, 0-240, 0-264, 0-288, 0-312, 0-336, 0-360, 0-384, 0-408, 0-432, 0-456, 0-480, 0-648, 0-672, 0-816, 0-840, 0-984, and 0-1008 hours
Part 1: Mean Amount of Total Radioactivity Expressed as a Percentage of the Radioactive Dose Administered (Fe) of [14C]-GDC-9545 Recovered in Urine, Feces, and Total (Urine and Feces Combined) by Collection Interval
Following a single oral dose of 30 milligrams of \[14C\]-GDC-9545, urine and fecal samples were collected over time from each participant. The amounts of total radioactivity excreted in the samples were determined using liquid scintillation counting. The lower limits of detection in urine and fecal samples were 0.423 and 8.36 nanogram equivalent of free drug per gram of sample, respectively. Following Day 21 (480 hours), where urine/fecal collections were no longer continuous and spot sampling days commenced, interpolation of Ae was calculated to estimate the amount excreted on non-collection days (collection intervals with interpolated values included 480-648 hours, 672-816 hours, and 840-984 hours).
Time frame: 0-12, 12-24, 0-24, 24-48, 48-72, 72-96, 96-120, 120-144, 144-168, 168-192, 192-216, 216-240, 240-264, 264-288, 288-312, 312-336, 336-360, 360-384, 384-408, 408-432, 432-456, 456-480, 480-648, 648-672, 672-816, 816-840, 840-984, & 984-1008 hours
Part 1: Mean Cumulative Amount of Total Radioactivity Expressed as a Percentage of the Radioactive Dose Administered (CumFe) of [14C]-GDC-9545 Recovered in Urine, Feces, and Total (Urine and Feces Combined) by Cumulative Collection Interval
Following a single oral dose of 30 milligrams of \[14C\]-GDC-9545, urine and fecal samples were collected over time from each participant. The amounts of total radioactivity excreted in the samples were determined using liquid scintillation counting. The lower limits of detection in urine and fecal samples were 0.423 and 8.36 nanogram equivalent of free drug per gram of sample, respectively. Following Day 21 (480 hours), where urine/fecal collections were no longer continuous and spot sampling days commenced, interpolation of Ae was calculated to estimate the amount excreted on non-collection days (collection intervals with interpolated values included 480-648 hours, 672-816 hours, and 840-984 hours).
Time frame: 0-24, 0-48, 0-72, 0-96, 0-120, 0-144, 0-168, 0-192, 0-216, 0-240, 0-264, 0-288, 0-312, 0-336, 0-360, 0-384, 0-408, 0-432, 0-456, 0-480, 0-648, 0-672, 0-816, 0-840, 0-984, and 0-1008 hours
Part 1: Maximum Observed Concentration (Cmax), Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma and Whole Blood
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting. The unit of measure for the total radioactivity concentrations is nanogram equivalent of free drug per millilitre.
Time frame: Pre-dose and 1, 1.5, 2, 2.5, 3, 5, 6, 8, and 12 hours post-dose on Day 1, daily from Day 2 to Day 21, and Days 28, 35, and 42
Part 1: Time to Maximum Observed Concentration (Tmax), Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma and Whole Blood
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting.
Time frame: Pre-dose and 1, 1.5, 2, 2.5, 3, 5, 6, 8, and 12 hours post-dose on Day 1, daily from Day 2 to Day 21, and Days 28, 35, and 42
Part 1: Area Under the Concentration-Time Curve From Time 0 to 72 Hours [AUC(0-72)], Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma and Whole Blood
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting.
Time frame: Pre-dose and post-dose at 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, and 72 hours
Part 1: Area Under the Concentration-Time Curve From Time 0 to the Time of Last Measurable Concentration [AUC(0-t)], Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma and Whole Blood
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting.
Time frame: Pre-dose and 1, 1.5, 2, 2.5, 3, 5, 6, 8, and 12 hours post-dose on Day 1, daily from Day 2 to Day 21, and Days 28, 35, and 42
Part 1: Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)], Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity (TR) concentrations in plasma and whole blood were determined using liquid scintillation counting.
Time frame: Pre-dose and 1, 1.5, 2, 2.5, 3, 5, 6, 8, and 12 hours post-dose on Day 1, daily from Day 2 to Day 21, and Days 28, 35, and 42
Part 1: Terminal Elimination Half-Life (t1/2), Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma and Whole Blood
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity (TR) concentrations in plasma and whole blood were determined using liquid scintillation counting.
Time frame: Pre-dose and 1, 1.5, 2, 2.5, 3, 5, 6, 8, and 12 hours post-dose on Day 1, daily from Day 2 to Day 21, and Days 28, 35, and 42
Part 1: First Order Rate Constant Associated With Terminal Portion of the Curve (λz), Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma and Whole Blood
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting.
Time frame: Pre-dose and 1, 1.5, 2, 2.5, 3, 5, 6, 8, and 12 hours post-dose on Day 1, daily from Day 2 to Day 21, and Days 28, 35, and 42
Part 1: Total Body Clearance Calculated After a Single Extravascular Administration Where Fraction of Dose Bioavailable is Unknown (CL/F), Estimated for GDC-9545 in Plasma
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting.
Time frame: Pre-dose and 1, 1.5, 2, 2.5, 3, 5, 6, 8, and 12 hours post-dose on Day 1, daily from Day 2 to Day 21, and Days 28, 35, and 42
Part 1: Apparent Volume of Distribution Where Fraction of Dose Bioavailable is Unknown (Vz/F), Estimated for GDC-9545 in Plasma
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting.
Time frame: Pre-dose and 1, 1.5, 2, 2.5, 3, 5, 6, 8, and 12 hours post-dose on Day 1, daily from Day 2 to Day 21, and Days 28, 35, and 42
Part 1: Total Radioactivity Concentrations of [14C]-GDC-9545 in Plasma and Whole Blood at Specified Timepoints
Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting. For calculation of the geometric mean, values reported as not detectable have been set to 0.5× the limit of detection (LOD); the LOD was 11.0 nanogram equivalent of free drug per millilitre (mL).
Time frame: Postdose at 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours
Part 1: Whole Blood to Plasma Total Radioactivity Concentration Ratios of [14C]-GDC-9545 at Specified Timepoints
Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting. The limit of detection was 11.0 nanogram equivalent of free drug per millilitre (mL).
Time frame: Postdose at 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours
Part 2: Absolute Bioavailability (F) of GDC-9545/F12 and /F18 Capsules Calculated Relative to GDC-9545 Solution for Infusion Based on the Adjusted AUC(0-∞), Estimated in Plasma Samples
Absolute bioavailability of the GDC-9545/F12 and /F18 capsules were calculated relative to GDC-9545 solution for infusion based on the adjusted geometric mean AUC(0-∞) values obtained after oral and intravenous (IV) administration of GDC-9545. Log-transformed AUC(0-∞) was analyzed using mixed effects modelling techniques. The model included terms for treatment and sequence fitted as fixed effects and subject within sequence fitted as a random effect.
Time frame: For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8
Part 2: Relative Bioavailability Based on the Adjusted Cmax (Frel Cmax) of the GDC-9545/F18 Capsule Calculated Relative to the GDC-9545/F12 Capsule, Estimated in Plasma Samples
Relative bioavailability of the GDC-9545/F18 capsule was calculated relative to the GDC-9545/F12 capsule based on the adjusted geometric mean Cmax values. Log-transformed Cmax was analyzed using mixed effects modelling techniques. The model included terms for treatment, sequence, and period fitted as fixed effects and subject nested within sequence as a random effect.
Time frame: For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8
Part 2: Relative Bioavailability Based on the Adjusted AUC(0-∞) [Frel AUC(0-∞)] of the GDC-9545/F18 Capsule Calculated Relative to the GDC-9545/F12 Capsule, Estimated in Plasma Samples
Relative bioavailability of the GDC-9545/F18 capsule was calculated relative to the GDC-9545/F12 capsule based on the adjusted geometric mean AUC(0-∞) values. Log-transformed AUC(0-∞) was analyzed using mixed effects modelling techniques. The model included terms for treatment, sequence, and period fitted as fixed effects and subject nested within sequence as a random effect.
Time frame: For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8
Part 2: Relative Bioavailability Based on the Adjusted AUC(0-t) [Frel AUC(0-t)] of GDC-9545/F18 Capsule Calculated Relative to GDC-9545/F12 Capsule, Estimated in Plasma Samples
Relative bioavailability of the GDC-9545/F18 capsule was calculated relative to the GDC-9545/F12 capsule based on the adjusted geometric mean AUC(0-t) values. Log-transformed AUC(0-t) was analyzed using mixed effects modelling techniques. The model included terms for treatment, sequence, and period fitted as fixed effects and subject nested within sequence as a random effect.
Time frame: For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8
Part 2: Cmax for GDC-9545 Solution for Infusion and GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.
Time frame: For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8
Part 2: Tmax for GDC-9545 Solution for Infusion and GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.
Time frame: For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8
Part 2: AUC(0-t) for GDC-9545 Solution for Infusion and GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.
Time frame: For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8
Part 2: AUC(0-∞) for GDC-9545 Solution for Infusion and GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.
Time frame: For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8
Part 2: t1/2 for GDC-9545 Solution for Infusion and GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.
Time frame: For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8
Part 2: First Order Rate Constant Associated With Terminal Portion of the Curve (λz) for GDC-9545 Solution for Infusion and GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.
Time frame: For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8
Part 2: Total Body Clearance (CL) After a Single IV Administration for GDC-9545 Solution for Infusion, Estimated in Plasma Samples
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.
Time frame: For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8
Part 2: Total Body Clearance Calculated After a Single Extravascular Administration Where Fraction of Dose Bioavailable is Unknown (CL/F) for GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.
Time frame: For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8
Part 2: Volume of Distribution Based on the Terminal Phase Calculated Using AUC(0-∞) After a Single IV Administration (Vz) for GDC-9545 Solution for Infusion, Estimated in Plasma Samples
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.
Time frame: For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8
Part 2: Apparent Volume of Distribution Based on the Terminal Phase Calculated With AUC(0-∞) After a Single Extravascular Administration Where Fraction of Dose Bioavailable is Unknown (Vz/F) for GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.
Time frame: For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8
Parts 1 and 2: Number of Participants With at Least One Adverse Event, With Severity Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)
All adverse events (AEs) were recorded and the investigator independently assessed the seriousness and severity of each AE. AE severity was graded on a scale from 1 to 5 using the NCI-CTCAE v5.0; any events not specifically listed in the scale were defined as: Grade 1 is mild; Grade 2 is moderate; Grade 3 is severe or medically significant; Grade 4 is life-threatening; and Grade 5 is death related to an AE. AEs of special interest were: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law; Cases of potential drug-induced kidney injury; Grade ≥3 nausea/vomiting/diarrhea; Grade ≥2 thromboembolic events; Grade ≥3 renal failure; Grade ≥3 hepatitis or elevation in ALT or AST; Grade ≥2 vaginal or uterine hemorrhage; Grade ≥2 bradycardia; Any grade of endometrial cancer; and, Suspected transmission of an infectious agent by the study drug.
Time frame: From Baseline until end of study (up to 42 days and 35 days for Parts 1 and 2, respectively)
Parts 1 and 2: Number of Participants With at Least One Abnormality in Laboratory Safety Tests, Reported as Adverse Events
Participants provided blood samples at the specified timepoints for laboratory analysis of clinical chemistry, hematology, and coagulation panels (please refer to Appendices 1 and 2 of the protocol for a complete list). Any of the laboratory test results that were outside of a parameter's normal reference range were considered abnormalities. Not every laboratory abnormality qualified as an adverse event (AE). A laboratory test result was reported as an AE if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment.
Time frame: Part 1: Baseline and Discharge Day (up to 21 days); Part 2: Baseline, Day -1 of each of the 3 treatment periods, and Discharge Day (up to 29 days)
Parts 1 and 2: Number of Participants With at Least One Abnormality in Vital Sign Measurements, Reported as Adverse Events
Vital sign measurements included pulse rate, systolic and diastolic blood pressure while the participant was in a supine position for 5 minutes, and oral temperature. Any of the vital sign results that were outside of a parameter's normal range were considered abnormalities. Not every vital sign abnormality qualified as an adverse event (AE). A vital sign result was reported as an AE if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment.
Time frame: Part 1: Baseline, predose and 1, 4, and 24 hours postdose, and Discharge Day (up to 21 days); Part 2: Baseline, predose and 0.5, 1, 4, and 24 hours postdose for each of the 3 treatment periods, and Discharge Day (up to 29 days)
Parts 1 and 2: Number of Participants With at Least One Abnormality in 12-Lead Electrocardiogram Measurements, Reported as Adverse Events
The 12-lead electrocardiograms (ECG) recorded measurements of heart rate, and PR, RR, QRS, uncorrected QT, and QTcF intervals. Any of the ECG parameter results that were outside of the normal range were considered abnormalities. Not every ECG abnormality qualified as an adverse event (AE). An ECG result was reported as an AE if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment.
Time frame: Part 1: Baseline (Day 1, predose), 1, 4, and 24 hours postdose, and Discharge Day (up to 21 days); Part 2: Baseline (Day 1, predose), 0.5, 1, 4, and 24 hours postdose for each of the 3 treatment periods, and Discharge Day (up to 29 days)
| Milestone | Part 1: [14C]-GDC-9545 | Part 2: GDC-9545 Treatment Sequence BCD | Part 2: GDC-9545 Treatment Sequence BDC |
|---|---|---|---|
| Started | 6 | 5 | 5 |
| Part 1: received the planned dose of study drug | 6 | 0 | 0 |
| Part 2: received all 3 planned doses of study drug | 0 | 5 | 5 |
| Completed | 6 | 5 | 5 |
| Not completed | 0 | 0 | 0 |
Following a single oral dose of 30 milligrams of \[14C\]-GDC-9545, urine and fecal samples were collected over time from each participant. The amounts of total radioactivity excreted in the samples were determined using liquid scintillation counting. The lower limits of detection in urine and fecal samples were 0.423 and 8.36 nanogram equivalent of free drug per gram of sample, respectively. Following Day 21 (480 hours), where urine/fecal collections were no longer continuous and spot sampling days commenced, interpolation of Ae was calculated to estimate the amount excreted on non-collection days (collection intervals with interpolated values included 480-648 hours, 672-816 hours, and 840-984 hours).
| milligram equivalent of free drug | Part 1: [14C]-GDC-9545 - Urine | Part 1: [14C]-GDC-9545 - Feces | Part 1: [14C]-GDC-9545 - Total (Urine and Feces) |
|---|---|---|---|
| Part 1: Mean Cumulative Amount of Total Radioactivity (CumAe) of [14C]-GDC-9545 Excreted in Urine, Feces, and Total (Urine and Feces Combined) Over the Entire Collection Period | 2.78 ± 0.503 | 20.70 ± 0.712 | 23.50 ± 0.952 |
Following a single oral dose of 30 milligrams of \[14C\]-GDC-9545, urine and fecal samples were collected over time from each participant. The amounts of total radioactivity excreted in the samples were determined using liquid scintillation counting. The lower limits of detection in urine and fecal samples were 0.423 and 8.36 nanogram equivalent of free drug per gram of sample, respectively. Following Day 21 (480 hours), where urine/fecal collections were no longer continuous and spot sampling days commenced, interpolation of Ae was calculated to estimate the amount excreted on non-collection days (collection intervals with interpolated values included 480-648 hours, 672-816 hours, and 840-984 hours).
| Percentage of radioactive dose | Part 1: [14C]-GDC-9545 - Urine | Part 1: [14C]-GDC-9545 - Feces | Part 1: [14C]-GDC-9545 - Total (Urine and Feces) |
|---|---|---|---|
| Part 1: Mean Cumulative Amount of Total Radioactivity Expressed as a Percentage of the Radioactive Dose Administered (CumFe) of [14C]-GDC-9545 Recovered in Urine, Feces, and Total (Urine and Feces Combined) Over the Entire Collection Period | 9.039 ± 1.634 | 67.410 ± 2.313 | 77.012 ± 2.794 |
Following a single oral dose of 30 milligrams of \[14C\]-GDC-9545, urine and fecal samples were collected over time from each participant. The amounts of total radioactivity excreted in the samples were determined using liquid scintillation counting. The lower limits of detection in urine and fecal samples were 0.423 and 8.36 nanogram equivalent of free drug per gram of sample, respectively. Following Day 21 (480 hours), where urine/fecal collections were no longer continuous and spot sampling days commenced, interpolation of Ae was calculated to estimate the amount excreted on non-collection days (collection intervals with interpolated values included 480-648 hours, 672-816 hours, and 840-984 hours).
| nanogram equivalent of free drug | Part 1: [14C]-GDC-9545 - Urine | Part 1: [14C]-GDC-9545 - Feces | Part 1: [14C]-GDC-9545 - Total (Urine and Feces) |
|---|---|---|---|
| 0-12 hours | 668000 ± 78600 | — | — |
| 12-24 hours | 307000 ± 54300 | — | — |
| 0-24 hours | — | 6980 ± 17100 | 982000 ± 140000 |
| 24-48 hours | 410000 ± 56400 | 1980000 ± 3240000 | 2390000 ± 3250000 |
| 48-72 hours | 242000 ± 50600 | 3880000 ± 4230000 | 4120000 ± 4200000 |
| 72-96 hours | 174000 ± 54800 | 5730000 ± 4420000 | 5900000 ± 4380000 |
| 96-120 hours | 129000 ± 48000 | 902000 ± 746000 | 1030000 ± 761000 |
| 120-144 hours | 94100 ± 41100 | 2330000 ± 2590000 | 2420000 ± 2620000 |
| 144-168 hours | 56100 ± 22000 | 1180000 ± 894000 | 1240000 ± 905000 |
| 168-192 hours | 54300 ± 20300 | 453000 ± 357000 | 507000 ± 352000 |
| 192-216 hours | 49900 ± 21900 | 438000 ± 596000 | 488000 ± 603000 |
| 216-240 hours | 27700 ± 13600 | 732000 ± 1010000 | 760000 ± 1020000 |
| 240-264 hours | 35300 ± 13300 | 424000 ± 349000 | 459000 ± 358000 |
| 264-288 hours | 30000 ± 9410 | 470000 ± 633000 | 500000 ± 639000 |
| 288-312 hours | 27800 ± 9520 | 198000 ± 178000 | 226000 ± 187000 |
| 312-336 hours | 23200 ± 5850 | 188000 ± 159000 | 211000 ± 162000 |
| 336-360 hours | 25200 ± 4160 | 63700 ± 66000 | 88800 ± 67100 |
| 360-384 hours | 20300 ± 5510 | 159000 ± 68800 | 179000 ± 70700 |
| 384-408 hours | 17600 ± 3550 | 122000 ± 95300 | 139000 ± 96700 |
| 408-432 hours | 20800 ± 4430 | 69100 ± 50400 | 89900 ± 51200 |
| 432-456 hours | 17300 ± 2920 | 73500 ± 54000 | 90700 ± 55900 |
| 456-480 hours | 16300 ± 2940 | 82000 ± 45000 | 98200 ± 46000 |
| 480-648 hours | 114000 ± 22100 | 305000 ± 273000 | 401000 ± 161000 |
| 648-672 hours | 16300 ± 3820 | 44300 ± 48600 | 60600 ± 51700 |
| 672-816 hours | 93100 ± 19200 | 362000 ± 296000 | 493000 ± 267000 |
| 816-840 hours | 14700 ± 2830 | 88800 ± 70800 | 104000 ± 72300 |
| 840-984 hours | 83900 ± 15500 | 412000 ± 291000 | 496000 ± 300000 |
| 984-1008 hours | 13300 ± 2430 | 48500 ± 30200 | 61800 ± 32000 |
Following a single oral dose of 30 milligrams of \[14C\]-GDC-9545, urine and fecal samples were collected over time from each participant. The amounts of total radioactivity excreted in the samples were determined using liquid scintillation counting. The lower limits of detection in urine and fecal samples were 0.423 and 8.36 nanogram equivalent of free drug per gram of sample, respectively. Following Day 21 (480 hours), where urine/fecal collections were no longer continuous and spot sampling days commenced, interpolation of Ae was calculated to estimate the amount excreted on non-collection days (collection intervals with interpolated values included 480-648 hours, 672-816 hours, and 840-984 hours).
| nanogram equivalent of free drug | Part 1: [14C]-GDC-9545 - Urine | Part 1: [14C]-GDC-9545 - Feces | Part 1: [14C]-GDC-9545 - Total (Urine and Feces) |
|---|---|---|---|
| 0-24 hours | 975000 ± 128000 | 6980 ± 17100 | 982000 ± 140000 |
| 0-48 hours | 1380000 ± 175000 | 1980000 ± 3230000 | 3370000 ± 3230000 |
| 0-72 hours | 1630000 ± 215000 | 5860000 ± 4840000 | 7490000 ± 4750000 |
| 0-96 hours | 1800000 ± 262000 | 11600000 ± 5790000 | 13400000 ± 5640000 |
| 0-120 hours | 1930000 ± 299000 | 12500000 ± 5520000 | 14400000 ± 5330000 |
| 0-144 hours | 2020000 ± 334000 | 14800000 ± 3120000 | 16800000 ± 2880000 |
| 0-168 hours | 2080000 ± 352000 | 16000000 ± 2740000 | 18100000 ± 2510000 |
| 0-192 hours | 2130000 ± 370000 | 16500000 ± 2840000 | 18600000 ± 2590000 |
| 0-216 hours | 2180000 ± 389000 | 16900000 ± 2650000 | 19100000 ± 2380000 |
| 0-240 hours | 2210000 ± 401000 | 17600000 ± 1820000 | 19800000 ± 1540000 |
| 0-264 hours | 2250000 ± 413000 | 18100000 ± 1620000 | 20300000 ± 1340000 |
| 0-288 hours | 2280000 ± 421000 | 18500000 ± 1280000 | 20800000 ± 1030000 |
| 0-312 hours | 2300000 ± 430000 | 18700000 ± 1160000 | 21000000 ± 940000 |
| 0-336 hours | 2330000 ± 436000 | 18900000 ± 1110000 | 21200000 ± 920000 |
| 0-360 hours | 2350000 ± 439000 | 19000000 ± 1120000 | 21300000 ± 932000 |
| 0-384 hours | 2370000 ± 445000 | 19100000 ± 1110000 | 21500000 ± 934000 |
| 0-408 hours | 2390000 ± 448000 | 19300000 ± 1060000 | 21600000 ± 894000 |
| 0-432 hours | 2410000 ± 451000 | 19300000 ± 1070000 | 21700000 ± 893000 |
| 0-456 hours | 2430000 ± 454000 | 19400000 ± 1030000 | 21800000 ± 854000 |
| 0-480 hours | 2450000 ± 456000 | 19500000 ± 1050000 | 21900000 ± 878000 |
| 0-648 hours | 2560000 ± 473000 | 19800000 ± 1010000 | 22300000 ± 966000 |
| 0-672 hours | 2580000 ± 475000 | 19800000 ± 969000 | 22400000 ± 922000 |
| 0-816 hours | 2670000 ± 488000 | 20200000 ± 742000 | 22900000 ± 825000 |
| 0-840 hours | 2680000 ± 490000 | 20300000 ± 733000 | 23000000 ± 847000 |
| 0-984 hours | 2770000 ± 501000 | 20700000 ± 719000 | 23500000 ± 949000 |
| 0-1008 hours | 2780000 ± 503000 | 20700000 ± 712000 | 23500000 ± 952000 |
Following a single oral dose of 30 milligrams of \[14C\]-GDC-9545, urine and fecal samples were collected over time from each participant. The amounts of total radioactivity excreted in the samples were determined using liquid scintillation counting. The lower limits of detection in urine and fecal samples were 0.423 and 8.36 nanogram equivalent of free drug per gram of sample, respectively. Following Day 21 (480 hours), where urine/fecal collections were no longer continuous and spot sampling days commenced, interpolation of Ae was calculated to estimate the amount excreted on non-collection days (collection intervals with interpolated values included 480-648 hours, 672-816 hours, and 840-984 hours).
| Percentage of radioactive dose | Part 1: [14C]-GDC-9545 - Urine | Part 1: [14C]-GDC-9545 - Feces | Part 1: [14C]-GDC-9545 - Total (Urine and Feces) |
|---|---|---|---|
| 0-12 hours | 2.172 ± 0.255 | — | — |
| 12-24 hours | 0.997 ± 0.176 | — | — |
| 0-24 hours | — | 0.023 ± 0.056 | 3.191 ± 0.454 |
| 24-48 hours | 1.331 ± 0.183 | 6.428 ± 10.516 | 7.759 ± 10.575 |
| 48-72 hours | 0.787 ± 0.164 | 12.603 ± 13.735 | 13.390 ± 13.639 |
| 72-96 hours | 0.566 ± 0.178 | 18.625 ± 14.351 | 19.191 ± 14.234 |
| 96-120 hours | 0.420 ± 0.156 | 2.932 ± 2.423 | 3.352 ± 2.472 |
| 120-144 hours | 0.306 ± 0.134 | 7.565 ± 8.420 | 7.871 ± 8.510 |
| 144-168 hours | 0.182 ± 0.072 | 3.848 ± 2.905 | 4.030 ± 2.941 |
| 168-192 hours | 0.176 ± 0.066 | 1.471 ± 1.159 | 1.647 ± 1.145 |
| 192-216 hours | 0.162 ± 0.071 | 1.424 ± 1.937 | 1.586 ± 1.961 |
| 216-240 hours | 0.090 ± 0.044 | 2.379 ± 3.280 | 2.469 ± 3.319 |
| 240-264 hours | 0.115 ± 0.043 | 1.377 ± 1.134 | 1.492 ± 1.164 |
| 264-288 hours | 0.098 ± 0.031 | 1.528 ± 2.056 | 1.626 ± 2.077 |
| 288-312 hours | 0.090 ± 0.031 | 0.644 ± 0.580 | 0.734 ± 0.608 |
| 312-336 hours | 0.075 ± 0.019 | 0.612 ± 0.518 | 0.687 ± 0.527 |
| 336-360 hours | 0.082 ± 0.014 | 0.207 ± 0.214 | 0.289 ± 0.218 |
| 360-384 hours | 0.066 ± 0.018 | 0.517 ± 0.224 | 0.583 ± 0.230 |
| 384-408 hours | 0.057 ± 0.012 | 0.396 ± 0.310 | 0.453 ± 0.314 |
| 408-432 hours | 0.068 ± 0.014 | 0.225 ± 0.164 | 0.292 ± 0.166 |
| 432-456 hours | 0.056 ± 0.009 | 0.239 ± 0.175 | 0.295 ± 0.182 |
| 456-480 hours | 0.053 ± 0.010 | 0.266 ± 0.146 | 0.319 ± 0.150 |
| 480-648 hours | 0.371 ± 0.072 | 0.993 ± 0.889 | 1.808 ± 0.518 |
| 648-672 hours | 0.053 ± 0.012 | 0.144 ± 0.158 | 0.197 ± 0.168 |
| 672-816 hours | 0.303 ± 0.062 | 1.178 ± 0.963 | 1.601 ± 0.868 |
| 816-840 hours | 0.048 ± 0.009 | 0.289 ± 0.230 | 0.337 ± 0.235 |
| 840-984 hours | 0.273 ± 0.050 | 1.339 ± 0.945 | 1.612 ± 0.974 |
| 984-1008 hours | 0.043 ± 0.008 | 0.158 ± 0.098 | 0.201 ± 0.104 |
Following a single oral dose of 30 milligrams of \[14C\]-GDC-9545, urine and fecal samples were collected over time from each participant. The amounts of total radioactivity excreted in the samples were determined using liquid scintillation counting. The lower limits of detection in urine and fecal samples were 0.423 and 8.36 nanogram equivalent of free drug per gram of sample, respectively. Following Day 21 (480 hours), where urine/fecal collections were no longer continuous and spot sampling days commenced, interpolation of Ae was calculated to estimate the amount excreted on non-collection days (collection intervals with interpolated values included 480-648 hours, 672-816 hours, and 840-984 hours).
| Percentage of radioactive dose | Part 1: [14C]-GDC-9545 - Urine | Part 1: [14C]-GDC-9545 - Feces | Part 1: [14C]-GDC-9545 - Total (Urine and Feces) |
|---|---|---|---|
| 0-24 hours | 3.169 ± 0.415 | 0.023 ± 0.056 | 3.191 ± 0.454 |
| 0-48 hours | 4.500 ± 0.570 | 6.451 ± 10.500 | 10.950 ± 10.498 |
| 0-72 hours | 5.286 ± 0.700 | 19.054 ± 15.718 | 24.340 ± 15.443 |
| 0-96 hours | 5.853 ± 0.850 | 37.679 ± 18.821 | 43.532 ± 18.320 |
| 0-120 hours | 6.272 ± 0.973 | 40.611 ± 17.941 | 46.884 ± 17.339 |
| 0-144 hours | 6.578 ± 1.086 | 48.176 ± 10.145 | 54.755 ± 9.345 |
| 0-168 hours | 6.761 ± 1.144 | 52.024 ± 8.919 | 58.785 ± 8.143 |
| 0-192 hours | 6.937 ± 1.203 | 53.495 ± 9.231 | 60.432 ± 8.410 |
| 0-216 hours | 7.099 ± 1.264 | 54.919 ± 8.629 | 62.018 ± 7.723 |
| 0-240 hours | 7.189 ± 1.303 | 57.298 ± 5.922 | 64.487 ± 4.999 |
| 0-264 hours | 7.304 ± 1.343 | 58.676 ± 5.269 | 65.979 ± 4.345 |
| 0-288 hours | 7.401 ± 1.369 | 60.204 ± 4.176 | 67.605 ± 3.358 |
| 0-312 hours | 7.492 ± 1.399 | 60.848 ± 3.784 | 68.339 ± 3.055 |
| 0-336 hours | 7.567 ± 1.416 | 61.459 ± 3.615 | 69.026 ± 2.990 |
| 0-360 hours | 7.649 ± 1.428 | 61.666 ± 3.645 | 69.315 ± 3.029 |
| 0-384 hours | 7.715 ± 1.445 | 62.183 ± 3.623 | 69.898 ± 3.035 |
| 0-408 hours | 7.772 ± 1.455 | 62.579 ± 3.453 | 70.351 ± 2.905 |
| 0-432 hours | 7.839 ± 1.467 | 62.804 ± 3.463 | 70.643 ± 2.903 |
| 0-456 hours | 7.895 ± 1.475 | 63.043 ± 3.346 | 70.938 ± 2.774 |
| 0-480 hours | 7.948 ± 1.483 | 63.309 ± 3.408 | 71.257 ± 2.853 |
| 0-648 hours | 8.319 ± 1.536 | 64.302 ± 3.285 | 73.065 ± 2.673 |
| 0-672 hours | 8.372 ± 1.543 | 64.446 ± 3.150 | 73.262 ± 2.540 |
| 0-816 hours | 8.675 ± 1.585 | 65.624 ± 2.412 | 74.863 ± 2.281 |
| 0-840 hours | 8.723 ± 1.592 | 65.913 ± 2.383 | 75.200 ± 2.365 |
| 0-984 hours | 8.995 ± 1.629 | 67.252 ± 2.336 | 76.812 ± 2.771 |
| 0-1008 hours | 9.039 ± 1.634 | 67.410 ± 2.313 | 77.012 ± 2.794 |
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting. The unit of measure for the total radioactivity concentrations is nanogram equivalent of free drug per millilitre.
| nanogram per millilitre (ng/mL) | Part 1: [14C]-GDC-9545 - GDC-9545 in Plasma | Part 1: [14C]-GDC-9545 - Total Radioactivity in Plasma | Part 1: [14C]-GDC-9545 - Total Radioactivity in Whole Blood |
|---|---|---|---|
| Part 1: Maximum Observed Concentration (Cmax), Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma and Whole Blood | 74.3 ± 31.2 | 124 ± 21.4 | 88.0 ± 25.8 |
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting.
| Hours | Part 1: [14C]-GDC-9545 - GDC-9545 in Plasma | Part 1: [14C]-GDC-9545 - Total Radioactivity in Plasma | Part 1: [14C]-GDC-9545 - Total Radioactivity in Whole Blood |
|---|---|---|---|
| Part 1: Time to Maximum Observed Concentration (Tmax), Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma and Whole Blood | 3.50 (2.00 to 5.00) | 5.00 (2.00 to 5.00) | 5.00 (2.50 to 5.00) |
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting.
| nanogram*hours per milliltre (ng*h/mL) | Part 1: [14C]-GDC-9545 - GDC-9545 in Plasma | Part 1: [14C]-GDC-9545 - Total Radioactivity in Plasma | Part 1: [14C]-GDC-9545 - Total Radioactivity in Whole Blood |
|---|---|---|---|
| Part 1: Area Under the Concentration-Time Curve From Time 0 to 72 Hours [AUC(0-72)], Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma and Whole Blood | 1930 ± 32.2 | 3370 ± 24.4 | 2530 ± 22.5 |
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting.
| nanogram*hours per milliltre (ng*h/mL) | Part 1: [14C]-GDC-9545 - GDC-9545 in Plasma | Part 1: [14C]-GDC-9545 - Total Radioactivity in Plasma | Part 1: [14C]-GDC-9545 - Total Radioactivity in Whole Blood |
|---|---|---|---|
| Part 1: Area Under the Concentration-Time Curve From Time 0 to the Time of Last Measurable Concentration [AUC(0-t)], Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma and Whole Blood | 2600 ± 43.8 | 4160 ± 40.3 | 3280 ± 40.9 |
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity (TR) concentrations in plasma and whole blood were determined using liquid scintillation counting.
| nanogram*hours per milliltre (ng*h/mL) | Part 1: [14C]-GDC-9545 - GDC-9545 in Plasma | Part 1: [14C]-GDC-9545 - Total Radioactivity in Plasma |
|---|---|---|
| Part 1: Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)], Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma | 2680 ± 43.2 | 6480 ± 39.2 |
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity (TR) concentrations in plasma and whole blood were determined using liquid scintillation counting.
| Hours | Part 1: [14C]-GDC-9545 - GDC-9545 in Plasma | Part 1: [14C]-GDC-9545 - Total Radioactivity in Plasma | Part 1: [14C]-GDC-9545 - Total Radioactivity in Whole Blood |
|---|---|---|---|
| Part 1: Terminal Elimination Half-Life (t1/2), Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma and Whole Blood | 42.6 ± 24.9 | 48.4 ± 29.4 | 50.8 ± 46.4 |
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting.
| 1/Hours | Part 1: [14C]-GDC-9545 - GDC-9545 in Plasma | Part 1: [14C]-GDC-9545 - Total Radioactivity in Plasma | Part 1: [14C]-GDC-9545 - Total Radioactivity in Whole Blood |
|---|---|---|---|
| Part 1: First Order Rate Constant Associated With Terminal Portion of the Curve (λz), Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma and Whole Blood | 0.0163 ± 24.9 | 0.0143 ± 29.4 | 0.0136 ± 46.4 |
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting.
| Litres per hour (L/h) | Part 1: [14C]-GDC-9545 - GDC-9545 in Plasma |
|---|---|
| Part 1: Total Body Clearance Calculated After a Single Extravascular Administration Where Fraction of Dose Bioavailable is Unknown (CL/F), Estimated for GDC-9545 in Plasma | 11.5 ± 43.2 |
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting.
| Litres per hour (L/h) | Part 1: [14C]-GDC-9545 - GDC-9545 in Plasma |
|---|---|
| Part 1: Apparent Volume of Distribution Where Fraction of Dose Bioavailable is Unknown (Vz/F), Estimated for GDC-9545 in Plasma | 705 ± 20.6 |
Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting. For calculation of the geometric mean, values reported as not detectable have been set to 0.5× the limit of detection (LOD); the LOD was 11.0 nanogram equivalent of free drug per millilitre (mL).
| nanogram equivalent of free drug/mL | Part 1: [14C]-GDC-9545 - Total Radioactivity in Plasma | Part 1: [14C]-GDC-9545 - Total Radioactivity in Whole Blood |
|---|---|---|
| 1 Hour | 64.7 ± 42.1 | 48.4 ± 32.9 |
| 1.5 Hours | 88.1 ± 29.2 | 66.7 ± 24.8 |
| 2 Hours | 111 ± 25.3 | 74.3 ± 26.3 |
| 2.5 Hours | 105 ± 25.1 | 76.7 ± 27.2 |
| 3 Hours | 108 ± 25.5 | 76.3 ± 24.9 |
| 4 Hours | 101 ± 22.3 | 74.4 ± 21.9 |
| 5 Hours | 123 ± 21.3 | 85.9 ± 22.3 |
| 6 Hours | 105 ± 18.9 | 70.4 ± 19.5 |
| 8 Hours | 89.1 ± 23.6 | 64.8 ± 22.2 |
| 12 Hours | 66.6 ± 22.5 | 52.3 ± 20.8 |
| 24 Hours | 45.6 ± 24.4 | 36.0 ± 26.2 |
| 48 Hours | 34.5 ± 29.5 | 24.6 ± 26.3 |
| 72 Hours | 22.7 ± 31.0 | 18.7 ± 25.0 |
| 96 Hours | 16.1 ± 64.5 | 9.97 ± 74.9 |
| 120 Hours | 9.88 ± 74.7 | 11.5 ± 64.4 |
| 144 Hours | 7.91 ± 60.3 | 7.92 ± 61.0 |
| 168 Hours | 6.64 ± 46.0 | 7.44 ± 49.2 |
Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting. The limit of detection was 11.0 nanogram equivalent of free drug per millilitre (mL).
| Ratio of concentrations (unitless) | Part 1: [14C]-GDC-9545 |
|---|---|
| 1 Hour | 0.747 ± 12.1 |
| 1.5 Hours | 0.758 ± 6.7 |
| 2 Hours | 0.673 ± 5.4 |
| 2.5 Hours | 0.732 ± 2.9 |
| 3 Hours | 0.704 ± 4.6 |
| 4 Hours | 0.738 ± 0.7 |
| 5 Hours | 0.700 ± 10.6 |
| 6 Hours | 0.672 ± 2.8 |
| 8 Hours | 0.728 ± 4.1 |
| 12 Hours | 0.786 ± 10.0 |
| 24 Hours | 0.789 ± 7.4 |
| 48 Hours | 0.713 ± 5.6 |
| 72 Hours | 0.825 ± 7.6 |
| 96 Hours | 0.757 ± 2.0 |
| 120 Hours | 1.00 ± 30.7 |
| 144 Hours | 1.02 ± 27.5 |
| 168 Hours | 0.843 ± NA |
Absolute bioavailability of the GDC-9545/F12 and /F18 capsules were calculated relative to GDC-9545 solution for infusion based on the adjusted geometric mean AUC(0-∞) values obtained after oral and intravenous (IV) administration of GDC-9545. Log-transformed AUC(0-∞) was analyzed using mixed effects modelling techniques. The model included terms for treatment and sequence fitted as fixed effects and subject within sequence fitted as a random effect.
| Percentage | Part 2, PK: GDC-9545/F12 Capsule (Treatment C) | Part 2, PK: GDC-9545/F18 Capsule (Treatment D) |
|---|---|---|
| Part 2: Absolute Bioavailability (F) of GDC-9545/F12 and /F18 Capsules Calculated Relative to GDC-9545 Solution for Infusion Based on the Adjusted AUC(0-∞), Estimated in Plasma Samples | 58.06 (53.45 to 63.07) | 58.70 (54.04 to 63.76) |
Relative bioavailability of the GDC-9545/F18 capsule was calculated relative to the GDC-9545/F12 capsule based on the adjusted geometric mean Cmax values. Log-transformed Cmax was analyzed using mixed effects modelling techniques. The model included terms for treatment, sequence, and period fitted as fixed effects and subject nested within sequence as a random effect.
| Percentage | Part 2, PK: GDC-9545/F18 Capsule (Treatment D) |
|---|---|
| Part 2: Relative Bioavailability Based on the Adjusted Cmax (Frel Cmax) of the GDC-9545/F18 Capsule Calculated Relative to the GDC-9545/F12 Capsule, Estimated in Plasma Samples | 100.79 (93.87 to 108.22) |
Relative bioavailability of the GDC-9545/F18 capsule was calculated relative to the GDC-9545/F12 capsule based on the adjusted geometric mean AUC(0-∞) values. Log-transformed AUC(0-∞) was analyzed using mixed effects modelling techniques. The model included terms for treatment, sequence, and period fitted as fixed effects and subject nested within sequence as a random effect.
| Percentage | Part 2, PK: GDC-9545/F18 Capsule (Treatment D) |
|---|---|
| Part 2: Relative Bioavailability Based on the Adjusted AUC(0-∞) [Frel AUC(0-∞)] of the GDC-9545/F18 Capsule Calculated Relative to the GDC-9545/F12 Capsule, Estimated in Plasma Samples | 102.04 (98.96 to 105.22) |
Relative bioavailability of the GDC-9545/F18 capsule was calculated relative to the GDC-9545/F12 capsule based on the adjusted geometric mean AUC(0-t) values. Log-transformed AUC(0-t) was analyzed using mixed effects modelling techniques. The model included terms for treatment, sequence, and period fitted as fixed effects and subject nested within sequence as a random effect.
| Percentage | Part 2, PK: GDC-9545/F18 Capsule (Treatment D) |
|---|---|
| Part 2: Relative Bioavailability Based on the Adjusted AUC(0-t) [Frel AUC(0-t)] of GDC-9545/F18 Capsule Calculated Relative to GDC-9545/F12 Capsule, Estimated in Plasma Samples | 101.97 (98.44 to 105.62) |
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.
| ng/mL | Part 2, PK: GDC-9545 Solution for Infusion (Treatment B) | Part 2, PK: GDC-9545/F12 Capsule (Treatment C) | Part 2, PK: GDC-9545/F18 Capsule (Treatment D) |
|---|---|---|---|
| Part 2: Cmax for GDC-9545 Solution for Infusion and GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples | 804 ± 32.3 | 94.1 ± 23.1 | 93.8 ± 31.1 |
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.
| hours | Part 2, PK: GDC-9545 Solution for Infusion (Treatment B) | Part 2, PK: GDC-9545/F12 Capsule (Treatment C) | Part 2, PK: GDC-9545/F18 Capsule (Treatment D) |
|---|---|---|---|
| Part 2: Tmax for GDC-9545 Solution for Infusion and GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples | 0.50 (0.25 to 0.60) | 5.00 (2.00 to 6.00) | 4.00 (2.00 to 5.00) |
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.
| ng*h/mL | Part 2, PK: GDC-9545 Solution for Infusion (Treatment B) | Part 2, PK: GDC-9545/F12 Capsule (Treatment C) | Part 2, PK: GDC-9545/F18 Capsule (Treatment D) |
|---|---|---|---|
| Part 2: AUC(0-t) for GDC-9545 Solution for Infusion and GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples | 5700 ± 33.3 | 3120 ± 35.3 | 3150 ± 39.2 |
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.
| ng*h/mL | Part 2, PK: GDC-9545 Solution for Infusion (Treatment B) | Part 2, PK: GDC-9545/F12 Capsule (Treatment C) | Part 2, PK: GDC-9545/F18 Capsule (Treatment D) |
|---|---|---|---|
| Part 2: AUC(0-∞) for GDC-9545 Solution for Infusion and GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples | 5630 ± 32.5 | 3270 ± 38.3 | 3300 ± 42.2 |
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.
| hours | Part 2, PK: GDC-9545 Solution for Infusion (Treatment B) | Part 2, PK: GDC-9545/F12 Capsule (Treatment C) | Part 2, PK: GDC-9545/F18 Capsule (Treatment D) |
|---|---|---|---|
| Part 2: t1/2 for GDC-9545 Solution for Infusion and GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples | 37.8 ± 33.9 | 35.2 ± 23.9 | 36.4 ± 21.6 |
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.
| 1/Hours | Part 2, PK: GDC-9545 Solution for Infusion (Treatment B) | Part 2, PK: GDC-9545/F12 Capsule (Treatment C) | Part 2, PK: GDC-9545/F18 Capsule (Treatment D) |
|---|---|---|---|
| Part 2: First Order Rate Constant Associated With Terminal Portion of the Curve (λz) for GDC-9545 Solution for Infusion and GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples | 0.0184 ± 33.9 | 0.0197 ± 23.9 | 0.0191 ± 21.6 |
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.
| Litres per hour (L/h) | Part 2, PK: GDC-9545 Solution for Infusion (Treatment B) |
|---|---|
| Part 2: Total Body Clearance (CL) After a Single IV Administration for GDC-9545 Solution for Infusion, Estimated in Plasma Samples | 5.31 ± 32.6 |
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.
| Litres per hour (L/h) | Part 2, PK: GDC-9545/F12 Capsule (Treatment C) | Part 2, PK: GDC-9545/F18 Capsule (Treatment D) |
|---|---|---|
| Part 2: Total Body Clearance Calculated After a Single Extravascular Administration Where Fraction of Dose Bioavailable is Unknown (CL/F) for GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples | 9.18 ± 38.3 | 9.08 ± 42.2 |
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.
| Litres (L) | Part 2, PK: GDC-9545 Solution for Infusion (Treatment B) |
|---|---|
| Part 2: Volume of Distribution Based on the Terminal Phase Calculated Using AUC(0-∞) After a Single IV Administration (Vz) for GDC-9545 Solution for Infusion, Estimated in Plasma Samples | 266 ± 21.5 |
Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.
| Litres (L) | Part 2, PK: GDC-9545/F12 Capsule (Treatment C) | Part 2, PK: GDC-9545/F18 Capsule (Treatment D) |
|---|---|---|
| Part 2: Apparent Volume of Distribution Based on the Terminal Phase Calculated With AUC(0-∞) After a Single Extravascular Administration Where Fraction of Dose Bioavailable is Unknown (Vz/F) for GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples | 466 ± 20.0 | 476 ± 24.5 |
All adverse events (AEs) were recorded and the investigator independently assessed the seriousness and severity of each AE. AE severity was graded on a scale from 1 to 5 using the NCI-CTCAE v5.0; any events not specifically listed in the scale were defined as: Grade 1 is mild; Grade 2 is moderate; Grade 3 is severe or medically significant; Grade 4 is life-threatening; and Grade 5 is death related to an AE. AEs of special interest were: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law; Cases of potential drug-induced kidney injury; Grade ≥3 nausea/vomiting/diarrhea; Grade ≥2 thromboembolic events; Grade ≥3 renal failure; Grade ≥3 hepatitis or elevation in ALT or AST; Grade ≥2 vaginal or uterine hemorrhage; Grade ≥2 bradycardia; Any grade of endometrial cancer; and, Suspected transmission of an infectious agent by the study drug.
| Participants | Part 1: [14C]-GDC-9545 | Part 2: GDC-9545 Solution for Infusion (Treatment B) | Part 2: GDC-9545/F12 Capsule (Treatment C) | Part 2: GDC-9545/F18 Capsule (Treatment D) | Part 2: Overall: Any GDC-9545 (Treatments B, C, or D) |
|---|---|---|---|---|---|
| Any Adverse Event (AE) | 3 | 5 | 3 | 4 | 9 |
| Serious AE | 0 | 0 | 0 | 0 | 0 |
| Grade 1 AE | 3 | 4 | 3 | 2 | 6 |
| Grade 2 AE | 0 | 1 | 0 | 2 | 3 |
| Grade ≥3 AE | 0 | 0 | 0 | 0 | 0 |
| AE Related to Study Drug | 0 | 1 | 1 | 1 | 3 |
| AE Leading to Withdrawal of Study Drug | 0 | 0 | 0 | 0 | 0 |
| AE of Special Interest | 0 | 0 | 0 | 0 | 0 |
Participants provided blood samples at the specified timepoints for laboratory analysis of clinical chemistry, hematology, and coagulation panels (please refer to Appendices 1 and 2 of the protocol for a complete list). Any of the laboratory test results that were outside of a parameter's normal reference range were considered abnormalities. Not every laboratory abnormality qualified as an adverse event (AE). A laboratory test result was reported as an AE if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment.
| Participants | Part 1: [14C]-GDC-9545 | Part 2: GDC-9545 Solution for Infusion (Treatment B) | Part 2: GDC-9545/F12 Capsule (Treatment C) | Part 2: GDC-9545/F18 Capsule (Treatment D) |
|---|---|---|---|---|
| Parts 1 and 2: Number of Participants With at Least One Abnormality in Laboratory Safety Tests, Reported as Adverse Events | 0 | 0 | 0 | 0 |
Vital sign measurements included pulse rate, systolic and diastolic blood pressure while the participant was in a supine position for 5 minutes, and oral temperature. Any of the vital sign results that were outside of a parameter's normal range were considered abnormalities. Not every vital sign abnormality qualified as an adverse event (AE). A vital sign result was reported as an AE if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment.
| Participants | Part 1: [14C]-GDC-9545 | Part 2: GDC-9545 Solution for Infusion (Treatment B) | Part 2: GDC-9545/F12 Capsule (Treatment C) | Part 2: GDC-9545/F18 Capsule (Treatment D) |
|---|---|---|---|---|
| Parts 1 and 2: Number of Participants With at Least One Abnormality in Vital Sign Measurements, Reported as Adverse Events | 0 | 0 | 0 | 0 |
The 12-lead electrocardiograms (ECG) recorded measurements of heart rate, and PR, RR, QRS, uncorrected QT, and QTcF intervals. Any of the ECG parameter results that were outside of the normal range were considered abnormalities. Not every ECG abnormality qualified as an adverse event (AE). An ECG result was reported as an AE if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment.
| Participants | Part 1: [14C]-GDC-9545 | Part 2: GDC-9545 Solution for Infusion (Treatment B) | Part 2: GDC-9545/F12 Capsule (Treatment C) | Part 2: GDC-9545/F18 Capsule (Treatment D) |
|---|---|---|---|---|
| Parts 1 and 2: Number of Participants With at Least One Abnormality in 12-Lead Electrocardiogram Measurements, Reported as Adverse Events | 0 | 0 | 0 | 0 |
Collected over From Baseline until end of study (up to 42 days and 35 days for Parts 1 and 2, respectively). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: [14C]-GDC-9545 | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part 2: GDC-9545 Solution for Infusion (Treatment B) | 0/10 (0%) | 0/10 (0%) | 5/10 (50%) |
| Part 2: GDC-9545/F12 Capsule (Treatment C) | 0/10 (0%) | 0/10 (0%) | 3/10 (30%) |
| Part 2: GDC-9545/F18 Capsule (Treatment D) | 0/10 (0%) | 0/10 (0%) | 4/10 (40%) |
| Part 2: Overall: Any GDC-9545 (Treatments B, C, or D) | 0/10 (0%) | 0/10 (0%) | 9/10 (90%) |
| Event | Part 1: [14C]-GDC-9545 | Part 2: GDC-9545 Solution for Infusion (Treatment B) | Part 2: GDC-9545/F12 Capsule (Treatment C) | Part 2: GDC-9545/F18 Capsule (Treatment D) | Part 2: Overall: Any GDC-9545 (Treatments B, C, or D) |
|---|---|---|---|---|---|
| InsomniaPsychiatric disorders | 0/6 | 3/10 | 0/10 | 1/10 | 4/10 |
| DiarrhoeaGastrointestinal disorders | 0/6 | 1/10 | 1/10 | 0/10 | 2/10 |
| External ear painEar and labyrinth disorders | 1/6 | 0/10 | 0/10 | 0/10 | 0/10 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 1/6 | 0/10 | 0/10 | 0/10 | 0/10 |
| Injection site painGeneral disorders | 1/6 | 0/10 | 0/10 | 0/10 | 0/10 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 1/6 | 0/10 | 0/10 | 0/10 | 0/10 |
| DyspepsiaGastrointestinal disorders | 0/6 | 0/10 | 1/10 | 1/10 | 1/10 |
| FlatulenceGastrointestinal disorders | 0/6 | 0/10 | 1/10 | 0/10 | 1/10 |
| ToothacheGastrointestinal disorders | 0/6 | 1/10 | 0/10 | 0/10 | 1/10 |
| FatigueGeneral disorders | 0/6 | 0/10 | 1/10 | 0/10 | 1/10 |
The overall number of baseline participants includes a total of 16 participants who were enrolled in either Part 1 (N = 6) or Part 2 (N = 10) of the study.
| Age, Continuous(Years) | Part 1: [14C]-GDC-9545 | Part 2: GDC-9545 Treatment Sequence BCD | Part 2: GDC-9545 Treatment Sequence BDC | Total |
|---|---|---|---|---|
| Part 1 | 56.2 ± 3.5 | — | — | 56.2 ± 3.5 |
| Part 2 | — | 58.8 ± 5.6 | 57.6 ± 3.0 | 58.2 ± 4.3 |
| Sex: Female, Male(Participants) | Part 1: [14C]-GDC-9545 | Part 2: GDC-9545 Treatment Sequence BCD | Part 2: GDC-9545 Treatment Sequence BDC | Total |
|---|---|---|---|---|
| Part 1 — Female | 6 | — | — | 6 |
| Part 1 — Male | 0 | — | — | 0 |
| Part 2 — Female | — | 5 | 5 | 10 |
| Part 2 — Male | — | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: [14C]-GDC-9545 | Part 2: GDC-9545 Treatment Sequence BCD | Part 2: GDC-9545 Treatment Sequence BDC | Total |
|---|---|---|---|---|
| Part 1 — Hispanic or Latino | 0 | — | — | 0 |
| Part 1 — Not Hispanic or Latino | 6 | — | — | 6 |
| Part 1 — Unknown or Not Reported | 0 | — | — | 0 |
| Part 2 — Hispanic or Latino | — | 0 | 0 | 0 |
| Part 2 — Not Hispanic or Latino | — | 5 | 5 | 10 |
| Part 2 — Unknown or Not Reported | — | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part 1: [14C]-GDC-9545 | Part 2: GDC-9545 Treatment Sequence BCD | Part 2: GDC-9545 Treatment Sequence BDC | Total |
|---|---|---|---|---|
| Part 1 — American Indian or Alaska Native | 0 | — | — | 0 |
| Part 1 — Asian | 0 | — | — | 0 |
| Part 1 — Native Hawaiian or Other Pacific Islander | 0 | — | — | 0 |
| Part 1 — Black or African American | 0 | — | — | 0 |
| Part 1 — White | 6 | — | — | 6 |
| Part 1 — More than one race | 0 | — | — | 0 |
| Part 1 — Unknown or Not Reported | 0 | — | — | 0 |
| Part 2 — American Indian or Alaska Native | — | 0 | 0 | 0 |
| Part 2 — Asian | — | 0 | 0 | 0 |
| Part 2 — Native Hawaiian or Other Pacific Islander | — | 0 | 0 | 0 |
| Part 2 — Black or African American | — | 0 | 0 | 0 |
| Part 2 — White | — | 5 | 5 | 10 |
| Part 2 — More than one race | — | 0 | 0 | 0 |
| Part 2 — Unknown or Not Reported | — | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Ran from Jan 2021 to primary completion in Apr 2021, 3 months.
Results were first posted in Feb 2023, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Giredestrant